Physician profile
Thomas E Stout
NPI 1356875728
$921.21
in general payments reported to CMS, 2019-2025
12 companies · $735 in 2025
The $735 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $186 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $921.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $228.88 | 2024-2025 | Erleada, Akeega |
| Procept Biorobotics Corporation | $194.65 | 2025 | |
| Janssen Scientific Affairs, LLC | $189.37 | 2025 | Erleada |
| Sumitomo Pharma America, INC. | $54.40 | 2024-2025 | Orgovyx |
| Abbvie INC. | $46.40 | 2024-2025 | |
| Tolmar, INC. | $45.43 | 2025 | Eligard, Jatenzo |
| Intuitive Surgical, INC. | $43.56 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.73 | 2025 | |
| Ferring Pharmaceuticals INC. | $20.70 | 2024 | Adstiladrin |
| Immunitybio, INC. | $20.11 | 2024 | |
| Novartis Pharmaceuticals Corporation | $18.98 | 2024 | |
| Organon LLC | $18.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.